Business
Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination
Avant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAvant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination\n\n\n\n\n\nAvant Diagnostics, Amarantus Diagnostics and Theranostics Health Provide Updated Information for Conference Call to Discuss Business Combination\nPR Newswire\nSCOTTSDALE, Arizona, SAN FRANCISCO and GAITHERSBERG, Maryland, March 7, 2016\n\n\n\nSCOTTSDALE, Arizona, SAN FRANCISCO and GAITHERSBERG, Maryland, March 7, 2016 /PRNewswire/ --\n\nAvant Diagnostics, Inc. (OTCQB: AVDX), a biotechnology company focused on the development of oncology based diagnostics, Amarantus Diagnostics, Inc. (\"Amarantus Diagnostics\") a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (\"Amarantus BioScience\") (OTCQX: AMBS), and Theranostics Health, Inc., a medical diagnostic technology company, today announced that due to increased participation demand for the conference call to discuss the business combination with Theranostics Health, the 4:30pm ET conference call number has been changed. To access the conference call please use the updated dial-in information below.\n\nConference Call Details \n\nDate: Monday, March 7th, 2016 \n\nTime: 4:30 p.m. Eastern Time \n\nLive call: (U.S. & Canada): 800-895-1085 \n\nInternational: 785-424-1055 \n\nConference ID: 135394 \n\nInterested parties can also access the replay of this conference call by dialing (toll-free) - 844-488-7474 or 862-902-0129; access Code - 25664178.  The recorded version of the call will be available approximately four hours after the call and will be accessible for approximately one month.\n\nAbout Theranostics Health \n\nTHI is a leading developer of proteomic technologies for measuring the activation status of key signaling pathways that are instrumental in the development of companion diagnostics for molecular-targeted therapies. THI has used these proteomic technologies to support the drug development programs of most major pharmaceutical and biotechnology drug development companies. THI is also providing these testing capabilities to clinical oncologists to advance personalized medicine through its TheraLink® Diagnostic Assays. For more information please visit http://www.theranosticshealth.com.\n\nAbout Avant Diagnostics, Inc. \n\nAvant is a medical diag...